Terms: = Liver cancer AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E AND Prognosis
5 results:
1. SETD2 deficiency accelerates mds-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in mds.
Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
[TBL] [Abstract] [Full Text] [Related]
2. Clinical significance of serum 14-3-3 beta in patients with hepatocellular carcinoma.
Lin H; Jiao X; Yu B; Du J; Xu H; Dong A; Wan C
Cancer Biomark; 2017 Aug; 20(2):143-150. PubMed ID: 28869445
[TBL] [Abstract] [Full Text] [Related]
3. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
Damaj G; Joris M; Chandesris O; Hanssens K; Soucie E; Canioni D; Kolb B; Durieu I; Gyan E; Livideanu C; Chèze S; Diouf M; Garidi R; Georgin-Lavialle S; Asnafi V; Lhermitte L; Lavigne C; Launay D; Arock M; Lortholary O; Dubreuil P; Hermine O
PLoS One; 2014; 9(1):e85362. PubMed ID: 24465546
[TBL] [Abstract] [Full Text] [Related]
4. Mediterranean diet and hepatocellular carcinoma.
Turati F; Trichopoulos D; Polesel J; Bravi F; Rossi M; Talamini R; Franceschi S; Montella M; Trichopoulou A; La Vecchia C; Lagiou P
J Hepatol; 2014 Mar; 60(3):606-11. PubMed ID: 24240052
[TBL] [Abstract] [Full Text] [Related]
5. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the mds1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells.
Mochizuki N; Shimizu S; Nagasawa T; Tanaka H; Taniwaki M; Yokota J; Morishita K
Blood; 2000 Nov; 96(9):3209-14. PubMed ID: 11050005
[TBL] [Abstract] [Full Text] [Related]
